First Affiliated Hospital of Liaoning Medical University, Jinzhou 121001, China.
Fitoterapia. 2013 Mar;85:109-13. doi: 10.1016/j.fitote.2013.01.002. Epub 2013 Jan 17.
Danshen is one of the most famous herbs in the world, and more and more danshen-prescribed drugs interactions have been reported in recent years. Evaluation of inhibition potential of danshen's major ingredients towards UDP-glucuronosyltransferases (UGTs) will be helpful for understanding detailed mechanisms for danshen-drugs interaction. Therefore, the aim of the present study is to investigate the inhibitory situation of cryptotanshinone and dihydrotanshinone I towards UGT enzyme-catalyzed propofol glucuronidation. In vitro the human liver microsome (HLM) incubation system was used, and the results showed that cryptotanshinone and dihydrotanshinone I exhibited dose-dependent inhibition towards HLM-catalyzed propofol glucuronidation. Dixon plot and Lineweaver-Burk plot showed that the inhibition type was best fit to competitive inhibition type for both cryptotanshinone and dihydrotanshinone I. The second plot using the slopes from the Lineweaver-Burk plot versus the concentrations of cryptotanshinone or dihydrotanshinone I was employed to calculate the inhibition parameters (Ki) to be 0.4 and 1.7μM, respectively. Using the reported maximum plasma concentration (Cmax), the altered in vivo exposure of propofol increased by 10% and 8.2% for the co-administration of dihydrotanshinone I and cryptotanshinone, respectively. All these results indicated the possible danshen-propofol interaction due to the inhibition of dihydrotanshinone I and cryptotanshinone towards the glucuronidation reaction of propofol.
丹参是世界上最著名的草药之一,近年来越来越多的丹参处方药物相互作用被报道。评估丹参主要成分对 UDP-葡萄糖醛酸转移酶(UGTs)的抑制潜力将有助于了解丹参-药物相互作用的详细机制。因此,本研究旨在研究隐丹参酮和二氢丹参酮 I 对 UGT 酶催化的丙泊酚葡萄糖醛酸化的抑制情况。在体外使用人肝微粒体(HLM)孵育系统,结果表明隐丹参酮和二氢丹参酮 I 对 HLM 催化的丙泊酚葡萄糖醛酸化呈剂量依赖性抑制。Dixon 图和 Lineweaver-Burk 图显示,抑制类型最适合两种隐丹参酮和二氢丹参酮 I 的竞争性抑制类型。使用 Lineweaver-Burk 图的斜率相对于隐丹参酮或二氢丹参酮 I 的浓度的第二图来计算抑制参数(Ki)分别为 0.4 和 1.7μM。使用报告的最大血浆浓度(Cmax),二氢丹参酮 I 和隐丹参酮联合给药时,丙泊酚体内暴露增加了 10%和 8.2%。所有这些结果表明,由于二氢丹参酮 I 和隐丹参酮对丙泊酚葡萄糖醛酸化反应的抑制,可能会发生丹参-丙泊酚相互作用。